OZ Biosciences launch a new Transduction Enhancer: AAVBlast

• Direct contact technical support
• Find products for your research

AAVBlast is specifically designed to improve the transduction of adeno-associated viral vectors (AAV). These vectors are commonly used in gene therapy and biomedical research due to their ability to deliver genes into various types of cells. By enhancing transduction efficiency, AAVBlast enables more effective gene delivery, leading to more precise research results and more efficient gene therapies. Additionally, the use of AAVBlast can reduce the amount of viral vector needed to achieve effective results, thereby lowering costs and risks associated with viral vector use. The role of AAVBlast in transduction is to enhance the efficiency and precision of gene delivery, with significant implications for biomedical research and gene therapy.

The AAVBlast is a transduction enhancer that offers several advantages for research. Here are some key benefits of using AAVBlast in research:

• Improved Infection Efficiency: AAVBlast enhances the efficiency of AAV infection, particularly for cells that are challenging to transduce.
• Non-Toxicity: AAVBlast is non-toxic, making it compatible with in vivo experiments.
• Reduce viral vector usage: The use of AAVBlast allow to achieve the same transduction results with a lower viral titer, saving time and resources.
• Versatile: compatible with a wide variety of cell types.

These advantages make AAVBlast a valuable tool for gene therapy research.

AAVBlast protocol

AAVBlast applications

The AAVBlast transduction enhancer is recommended for improving AAV transduction across a wide range of cell types, from CD34+ hematopoietic stem cells to primary cells or cell lines such as HT1080 or SH-SY5Y.

AAVBlast is ideal for enhancing research and development, preclinical, and clinical transduction protocols for ex vivo gene therapies and CAR-T therapies. Here are some specific applications:

Ex Vivo Gene Therapies: AAVBlast can be used to improve the efficiency of AAV vector transduction in CD34+ hematopoietic stem cells. This can enable better expression of the gene of interest, which is crucial for the success of gene therapies.

CAR-T Therapies: AAVBlast can also be used to enhance transduction of T lymphocytes with AAV vectors carrying chimeric antigen receptors (CAR). This can increase the efficiency of CAR-T therapies by boosting the number of T cells expressing the CAR.

Stem Cell Research: AAVBlast can be used to enhance the transduction of stem cells with AAV vectors. This can be beneficial for stem cell research, including the study of stem cell differentiation and disease modeling.

Neurodegenerative Disease Research: AAVBlast can be used to improve transduction of neurons with AAV vectors. This is particularly useful for neurodegenerative disease research, where gene expression in neurons is often necessary

In summary, AAVBlast is a valuable tool for improving the efficiency of AAV transduction in a variety of research and clinical contexts. Its versatility and effectiveness make it a valuable addition to any laboratory working with AAV vectors.